12.01.2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of .
13.12.2023 - RAHWAY, N.J. / ACCESSWIRE / December 13, 2023 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has earned the top spot on Newsweek s annual list of America s Most Responsible Companies, ranking No. 1 overall for the first . Seite 1
07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for .
03.10.2023 - NORTHAMPTON, MA / ACCESSWIRE / October 3, 2023 / Merck & Co., Inc.Unique collaboration expands our clinical trials efforts to four Historically Black Medical School Clinical Trial Centers of ExcellenceIncreasing diversity in clinical trials plays a .
20.09.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for .